Since 1996, Activase (t-PA)—a recombinant tissue-plasminogen activator—has remained the only FDA-approved drug indicated for improving neurologic recovery and reducing the incidence of disability in adults with acute ischemic stroke.

• Clinical evidence demonstrates that the neurologic benefit outweighs the risk in eligible patients1-23
• Over a decade of real-world experience in >100,000 patients24,25
• Many studies support safety and efficacy1-23
• Protocol adherence is a key to success1-3,26

• *
• Defined by the National Institutes of Health (NIH) Stroke Scale score compared to baseline.

Activase (t-PA) for AMPE

Learn more about the treatment of acute massive pulmonary embolism.

Get to know our comprehensive fibrinolytic product line.

MOA

Click to view the mechanism of action (MOA) of Activase (t-PA)

Download the Activase (t-PA) slide kit

Demonstrates the importance of rapid diagnosis, appropriate treatment, and adherence to protocols.

Indication: Activase is indicated for the management of acute ischemic stroke in adults for improving neurological recovery and reducing the incidence of disability. Treatment should only be initiated within 3 hours after the onset of stroke symptoms, and after exclusion of intracranial hemorrhage by a cranial computerized tomography (CT) scan or other diagnostic imaging method sensitive for the presence of hemorrhage (see CONTRAINDICATIONS in the full prescribing information).

Safety Information: All thrombolytic agents increase the risk of bleeding, including intracranial bleeding, and should be used only in appropriate patients. Not all patients with acute ischemic stroke will be eligible for Activase therapy, including patients with evidence of recent or active bleeding; recent (within 3 months) intracranial or intraspinal surgery, serious head trauma, or previous stroke; uncontrolled high blood pressure; or impaired blood clotting.

Please see full prescribing information.